الولايات المتحدة · منصات وبيانات · Morningstar

Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

نشره Morningstar · الولايات المتحدة منذ 9 س

Data included dose levels of 6, 7 and 8 MBq. PSA50, PSA80 and PSA90 represent maximum PSA declines of at least 50%, 80% and 90% from baseline, respectively. No dose-limiting…

اقرأ المقال كاملًا على Morningstar سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.morningstar.com)

يستحق القراءة أيضًا

MarketBeat

2,406 International Business Machines Corporation $IBM Shares Sold by Culbertson A N & Co. Inc.

The Motley Fool

The Federal Reserve's Latest October Inflation Forecast Has Arrived, and It's Terrible News for Wall Street

Seeking Alpha

Eurozone flash composite PMI falls to 51.9 in October; services, and manufacturing expansion slows

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Investing.com

Kemira Q3 2026 slides: revenue rises but margins hit by cost inflation

Yahoo Finance